Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma

Nature Genetics

Volumn 44, Issue 10, 2012, Pages 1126-1130

  Diskin, Sharon J ^a,b,g   Capasso, Mario ^c,d   Schnepp, Robert W ^a   Cole, Kristina A ^a,b   Attiyeh, Edward F ^a,b   Hou, Cuiping ^a   Diamond, Maura ^a   Carpenter, Erica L ^a   Winter, Cynthia ^a   Lee, Hanna ^a   Jagannathan, Jayanti ^a   Latorre, Valeria ^a,e   Iolascon, Achille ^c,d   Hakonarson, Hakon ^a,b   Devoto, Marcella ^a,b,f   Maris, John M ^a,b,g  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^e UNIVERSITY OF CALABRIA   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ALLELE; ARTICLE; CANCER INHIBITION; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 6Q; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE SILENCING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HACE1 GENE; HOMOZYGOSITY; HUMAN; LIN28B GENE; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH;

CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 6; COHORT STUDIES; DNA-BINDING PROTEINS; GENE EXPRESSION; GENE FREQUENCY; GENE KNOCKDOWN TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; LINKAGE DISEQUILIBRIUM; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA INTERFERENCE; SEQUENCE ANALYSIS, DNA; TRANSCRIPTOME; UBIQUITIN-PROTEIN LIGASES;

EID: 84866887187     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2387     Document Type: Article

References (48)

1. Maris, J.M. Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202-2211 (2010).
2. Yu, A.L. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324-1334 (2010).
3. Mossé, Y.P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008).
4. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
5. Trochet, D. et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am. J. Hum. Genet. 74, 761-764 (2004).
6. Mosse, Y.P. et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am. J. Hum. Genet. 75, 727-730 (2004).
7. Maris, J.M. et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N. Engl. J. Med. 358, 2585-2593 (2008).
8. Capasso, M. et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat. Genet. 41, 718-723 (2009).
9. Wang, K. et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 469, 216-220 (2011).
10. Nguyen, B. et al. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility loci. PLoS Genet. 7, e1002026 (2011).
11. Diskin, S.J. et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature 459, 987-991 (2009).
12. Latorre, V. et al. Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans. Cancer Epidemiol. Biomarkers Prev. 21, 658-663 (2012).
13. Henderson, T.O. et al. Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study. J. Clin. Oncol. 29, 76-82 (2011).
14. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190-2191 (2010).
15. Anglesio, M.S. et al. Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum. Mol. Genet. 13, 2061-2074 (2004).
16. Hibi, K. et al. Aberrant methylation of the HACE1 gene is frequently detected in advanced colorectal cancer. Anticancer Res. 28, 1581-1584 (2008).
17. Sakata, M. et al. Methylation of HACE1 in gastric carcinoma. Anticancer Res. 29, 2231-2233 (2009).
18. Zhang, L. et al. The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. Nat. Med. 13, 1060-1069 (2007).
19. Zhao, J., Zhang, Z., Vucetic, Z., Soprano, K.J. & Soprano, D.R. HACE1: a novel repressor of RAR transcriptional activity. J. Cell. Biochem. 107, 482-493 (2009).
20. Slade, I. et al. Constitutional translocation breakpoint mapping by genome-wide paired-end sequencing identifies HACE1 as a putative Wilms tumour susceptibility gene. J. Med. Genet. 47, 342-347 (2010).
21. Piskounova, E. et al. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 147, 1066-1079 (2011).
22. Iliopoulos, D., Hirsch, H.A. & Struhl, K. An epigenetic switch involving NF-κB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 139, 693-706 (2009).
23. West, J.A. et al. A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature 460, 909-913 (2009).
24. Viswanathan, S.R. et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 41, 843-848 (2009).
25. Martinez, N.J. & Gregory, R.I. MicroRNA gene regulatory pathways in the establishment and maintenance of ESC identity. Cell Stem Cell 7, 31-35 (2010).
26. Melton, C., Judson, R.L. & Blelloch, R. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature 463, 621-626 (2010).
27. Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920 (2007).
28. Neale, G. et al. Molecular characterization of the pediatric preclinical testing panel. Clin. Cancer Res. 14, 4572-4583 (2008).
29. Zhu, H. et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 147, 81-94 (2011).
30. Yuan, J., Nguyen, C.K., Liu, X., Kanellopoulou, C. & Muljo, S.A. Lin28b reprograms adult bone marrow hematopoietic progenitors to mediate fetal-like lymphopoiesis. Science 335, 1195-1200 (2012).
31. Widén, E. et al. Distinct variants at LIN28B influence growth in height from birth to adulthood. Am. J. Hum. Genet. 86, 773-782 (2010).
32. Ong, K.K. et al. Genetic variation in LIN28B is associated with the timing of puberty. Nat. Genet. 41, 729-733 (2009).
33. Sulem, P. et al. Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche. Nat. Genet. 41, 734-738 (2009).
34. Permuth-Wey, J. et al. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res. 71, 3896-3903 (2011).
35. Bosse, K.R. et al. Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res. 72, 2068-2078 (2012).
36. Pruim, R.J. et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336-2337 (2010).
37. Molenaar, J.J. et al. Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer 51, 10-19 (2012).
38. Brodeur, G.M. et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 11, 1466-1477 (1993).
39. Shimada, H. et al. The International Neuroblastoma Pathology Classification (Shimada) System. Cancer 86, 364-372 (1999).
40. Mathew, P. et al. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a Pediatric Oncology Group study. Neoplasia 3, 105-109 (2001).
41. Look, A.T. et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J. Clin. Oncol. 9, 581-591 (1991).
42. Gunderson, K.L., Steemers, F.J., Lee, G., Mendoza, L.G. & Chee, M.S. A genome-wide scalable SNP genotyping assay using microarray technology. Nat. Genet. 37, 549-554 (2005).
43. Steemers, F.J. et al. Whole-genome genotyping with the single-base extension assay. Nat. Methods 3, 31-33 (2006).
44. Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
45. Howie, B., Marchini, J. & Stephens, M. Genotype imputation with thousands of genomes. G3 (Bethesda) 1, 457-470 (2011).
46. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906-913 (2007).
47. Cole, K.A. et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol. Cancer Res. 6, 735-742 (2008).
48. Kaplan, E.L. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assn. 53, 457-481 (1958).